How did doctors come to blame depression on brain chemicals?
The strange origin of this story lies in the roots of an Indian plant used by Mahatma Gandhi to treat his high blood pressure.
For centuries, traditional Ayurvedic medicine in India used the roots of a shrub called ‘Rauvolfia serpentina‘ (Indian snakeroot) to make Sarpagandha: a medicine that treated high blood pressure and mental illness.
Inspired by Ayurvedic practice, scientists extracted a chemical from the Indian snakeroot, developing one of the first drugs to treat hypertension. The drug was called reserpine.
In addition to its antihypertensive effect, reserpine also tranquillized horses and sedated excitable patients. And so, it also became one of the first antipsychotic drugs.
As more and more patients were prescribed reserpine for hypertension and schizophrenia, doctors noticed that some patients developed depression. When reserpine treatment was stopped and followed by rest or electric shock, the depression was reversed. Somehow, reserpine seemed to be causing depression.
Curiously, doctors noticed that patients being treated for tuberculosis (TB) became more joyful. These happy patients all took a drug designed to kill the bacteria causing tuberculosis. The name of that drug was iproniazid, and iproniazid–originally a TB drug–would become the world’s first antidepressant. [Iproniazid’s relationship to Nazi rockets is another story.]
The accidental effects of reserpine and iproniazid helped doctors stumble upon a revelatory theory. Reserpine made patients depressed. Iproniazid treated their depression. How did these findings relate to one another? What was the connection?
The solution to the problem lay in how these two drugs produce opposite effects on the brain’s chemistry.
Reserpine decreases the number of chemical messengers (called monoamine neurotransmitters) in the nervous system. On the other hand, iproniazid boosts the number of monoamine neurotransmitters.
Depression, doctors thought, was merely a lack of one or more monoamines. They called this theory “the monoamine hypothesis of depression.” Treating depression was thus possible by raising the concentrations of monoamines (e.g. noradrenaline, dopamine and serotonin). The monoamine hypothesis led to the development of new classes of drugs to treat mental illness.
We now know that the monoamine hypothesis has several shortcomings. Firstly, the observations related to reserpine were mostly erroneous. Certain drugs that boost monoamines are not antidepressants (e.g. cocaine), while other drugs that fail to increase monoamines are antidepressants (e.g. mianserin).
On top of that, the timing of the antidepressant drug effect and its therapeutic effect do not coincide. Antidepressants boost monoamines immediately, but the mood-enhancing effects in patients take weeks. The monoamine hypothesis theory subsequently became more elaborate and morphed into the ‘neurotransmitter receptor hypothesis of depression’. But that is yet another story.